Target intelligence / Profile preview

Novel transcript, antisense to EFS (ENSG00000259018)

Target
ENSG00000259018
Molecular classification
Non-coding RNA, Natural antisense transcript
01

Overview

ENSG00000259018 is a non-protein-coding natural antisense transcript (NAT) expressed from the strand opposite the EFS gene. NATs are pervasive in mammalian genomes and typically regulate gene expression of their sense partners through a range of mechanisms. These include transcriptional interference (where RNA polymerase activity on opposing strands impedes transcription), RNA masking (where antisense transcripts bind to sense RNA, interfering with splicing or translation), dsRNA-dependent mechanisms like RNA interference, and regulation of chromatin state. NATs tend to be low in abundance, poorly spliced, and often have context-dependent—sometimes tissue- or development-specific—expression and effects. There is no evidence that ENSG00000259018 encodes a protein, serves as a drug target, or plays a recognized direct role in any human disease. Its primary function is presumed to be the post-transcriptional or epigenetic regulation of EFS or nearby genes, as with other natural antisense transcripts.

Other names
novel transcript, antisense to EFSENSG00000259018
02

Mechanism of action

Not applicable; in the broader sense, NATs may function via mechanisms such as transcriptional interference, RNA masking, double-stranded RNA–dependent processes (including RNA interference or RNA editing), and chromatin remodeling

03

Biological functions

Regulation of gene expression (primarily at the transcriptional and post-transcriptional levels)Epigenetic regulationPossible involvement in chromatin remodeling, dsRNA formation, RNA masking, or transcriptional interference
04

Disease associations

None specifically attributed to ENSG00000259018. As a class, NATs are increasingly recognized as modulators in cancer, imprinting disorders, and other epigenetic phenomena, but there is no documented disease association for this specific transcript
05

Safety considerations

None known; NATs as a molecular class are not linked to specific safety/therapeutic challenges at the individual transcript level outside experimental contexts.

Beyond the preview

Go deeper on Novel transcript, antisense to EFS (ENSG00000259018).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Novel transcript, antisense to EFS (ENSG00000259018).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call